益气化浊方联合常规西药治疗慢性肾脏病Ⅲ~Ⅳ期临床研究
DOI:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R692.5

基金项目:


Clinical Study on Yiqi Huazhuo Prescription Combined with Routine Western Medi⁃ cine for Chronic Kidney Disease of Stage Ⅲ~Ⅳ
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:观察益气化浊方联合常规西药治疗慢性肾脏病Ⅲ~Ⅳ期的临床疗效。方法:选取88 例慢性肾脏病Ⅲ~Ⅳ期患者,按随机数字表法分为观察组45例与对照组43例,对照组给予前列地尔注射液治疗,观察组在对照组基础上给予益气化浊方治疗,疗程结束后比较2组临床疗效、中医证候积分及肾功能指标。结果:观察组临床总有效率为84.44%,对照组临床总有效率为62.79%,2 组比较,差异有统计学意义(P<0.05)。治疗前,2 组各项中医证候积分、血清尿素氮(BUN)、血清肌酐(SCr)、24 h 尿蛋白定量(Upr)、尿酸(UA)、肾小球滤过率(eGFR) 比较,差异无统计学意义(P>0.05)。治疗后,2 组主症、次症积分较治疗前明显降低(P<0.05),观察组各项中医证候积分明显低于对照组(P<0.05);2组BUN、UA、SCr、Upr水平较治疗前均明显降低(P<0.05),观察组BUN、UA、SCr、Upr 水平明显低于对照组(P<0.05),2 组eGFR 水平较治疗前明显提高,观察组eGFR水平高于对照组(P<0.05)。结论:益气化浊方联合常规西药治疗慢性肾脏病Ⅲ~Ⅳ期患者,有利于提高疗效,缓解临床症状,改善肾功能指标。

    Abstract:

    Abstract:Objective:To observe the clinical effect of Yiqi Huazhuo prescription combined with routine western medicine for chronic kidney disease of stage Ⅲ~Ⅳ. Methods:A total of 88 cases of patients with chronic kidney disease of stage Ⅲ~Ⅳ were included in the study and were divided into the observation group and the control group according to the random number table method,45 and 43 cases in each group respectively. The control group was treated with alprostadil injection,and the observation group was additionally treated with Yiqi Huazhuo prescription based on the treatment of the control group. After treatment, the clinical effect, the Chinese medicine syndrome scores and the indexes of the kidney function in the two groups were compared. Results: The total clinical effective rate was 62.79% in the control group and 84.44% in the observation group, the difference between the two groups was statistically significant(P<0.05). Before treatment, compared the Chinese medicine syndrome scores and the blood urea nitrogen(BUN),serum creatinine(SCr),24-hour urine protein ratio(Upr),uric acid(UA) and estimated glomerular filtration rate(eGFR),there was no significance in the difference(P> 0.05). After treatment,the main and secondary scores in the two groups were significantly decreased when compared with those before treatment(P<0.05),and the scores in the observation group were significantly lower than those in the control group(P<0.05);the levels of BUN,UA,SCr and Upr in the two groups were significantly decreased when compared with those before treatment(P<0.05), and the above levels in the observation group were significantly lower than those in the control group(P<0.05), the level of eGFR in the two groups were significantly higher than that before treatment, and the level of eGFR in the observation group was higher than that in the control group. Conclusion:The therapy of Yiqi Huazhuo prescription combined with routine western medicine in treating patients with chronic kidney disease of stage Ⅲ ~ Ⅳ is conductive to improving curative effect,relieving clinical symptoms and improving the indexes of the kidney function.

    参考文献
    相似文献
    引证文献
引用本文

鲁恒心.益气化浊方联合常规西药治疗慢性肾脏病Ⅲ~Ⅳ期临床研究[J].新中医,2020,52(8):100-103

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2020-04-25
  • 出版日期: